Determining the Safety of Antimicrobial Peptides, GATR3 and DRGN1, Against Host Cells and Red Blood Cells A

Simple item page
dc.contributor.advisorvan Hoek, Monique
dc.creatorCarpenter, Ashley
dc.date2022-12-01
dc.date.accessioned2023-06-14T12:05:03Z
dc.date.available2023-06-14T12:05:03Z
dc.description.abstractUp to half of all combat injured patients suffer from infectious complications, predominately with biofilm-forming, multidrug-resistant (MDR) bacteria. Biofilm management of chronic wounds is an increasingly recognized factor in the healing of these injured patients. Coupled with the lack of new antibiotics and the emerging antibiotic resistance crisis there exists an urgent need for new therapeutics. Antimicrobial peptides (AMPs) have shown potential as antibacterial and antibiofilm; therefore, AMPs are an attractive candidate for clinical development. The synthetic peptides DRGN1 and GATR3 are being studied, and have been Both peptides have shown to have antimicrobial and/or anti-biofilm activity against medically relevant bacteria including Staphylococcus aureus and Pseudomonas aeruginosa. This study aims to test the safety of these lead peptides, DRGN1 and GATR3, and their wound healing properties against host cells. To evaluate the cytotoxicity of the lead peptides, cell cytotoxicity and hemolysis assays will be performed using human epidermal keratinocytes, human red blood cells and a human liver cancer cell line, HepG2 cells. To quantitate the wound healing of HEKa cells a scratch assay will be performed and measured. The cytotoxicity, hemolysis, and scratch assays will be compared with the control peptides, LL-37 and ID-1018. The therapeutic index is the ratio between the concentration at which a drug is toxic versus the concentration at which a drug is effective. While the exact therapeutic index can not yet be measured, some estimation of it will be made for the peptides. The proposed study will test the safety of these antimicrobial peptides and help identify whether DRGN1 and GATR3 advance through the pre-clinical in vivo studies.
dc.description.noteThis thesis has been embargoed for 2 years.It will not be available until December 2024 at the earliest.
dc.format.mediummasters theses
dc.identifier.urihttps://hdl.handle.net/1920/13321
dc.language.isoen
dc.rightsCopyright 2022 Ashley Carpenter
dc.rights.urihttps://rightsstatements.org/vocab/InC/1.0
dc.subject.keywordsAntimicrobial peptide
dc.subject.keywordsAntimicrobial resistance
dc.subject.keywordsHemolysis
dc.subject.keywordsToxicity
dc.subject.keywordsTherapeutic index
dc.subject.keywordsWound
dc.titleDetermining the Safety of Antimicrobial Peptides, GATR3 and DRGN1, Against Host Cells and Red Blood Cells A
dc.typeText
thesis.degree.disciplineBiology
thesis.degree.grantorGeorge Mason University
thesis.degree.levelMaster's
thesis.degree.nameMaster of Science in Biology

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Carpenter_thesis_2022.pdf
Size:
896.64 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.52 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

College of Science